MAMMÔ 2026 Day 1 Highlights: From Early Detection and Precision Diagnostics to Treatment De-escalation and Global Breast Cancer Care
FDA Approved Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
Who Shaped Oncology in the First Half of 2026: Breaking Down Approvals by Indications
Armenia Grants World's First Marketing Authorizations for BOT+BAL in MSS mCRC
Enrique Grande: Exploring Long-Term Outcomes and Predictive Biomarkers of Pembrolizumab in Advanced Renal Cell Carcinoma
Emanuela Palmerini: Connecting, Learning and Advancing Oncology at OncoDaily Grand Rounds in Madrid
Bogda Koczwara Named Candidate for UICC Board of Directors 2026–2028
The Cancer Elimination Collaboration Welcomed Ophira Ginsburg and Dorothy Keefe to the University of Sydney
OncoDaily GI is the dedicated GI cancer platform of OncoDaily, focused on the rapidly evolving field of gastrointestinal oncology. It covers the full spectrum of GI malignancies, including colorectal, anal canal, gastric, gastroesophageal junction (GEJ), esophageal, small bowel, pancreatic, hepatocellular, and biliary tract cancers. Through OncoDaily GI, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in the field.
